Introduction
============

> "Let food be thy medicine and medicine be thy food."
>
> Hippocrates (460 -- 370 BC)

Every year peptic ulcer and gastric cancer takes approximately 301,000 and 740,000 lives, respectively ([@B77]; [@B69]). Although both diseases have multiple etiologies like stress, diet, smoking and host genetic background, *Helicobacter pylori* infection is perhaps the most critical among them ([@B59]). However, every *H. pylori* infected individual does not develop peptic ulcer or gastric cancer. More than half of the world population is infected by *H. pylori*, but 10--20% of the infected people suffer from these diseases ([@B27]). Why ∼80% of the *H. pylori* infected people in any given population never suffer from gastric disorders is unknown at present. Also, the clinical outcomes among the *H. pylori* infected population suffering from gastric disorders vary tremendously with geography ([@B16]). For example, gastric cancer is fairly common in East-Asian countries like Japan and Korea, but in most African countries and India, the incidence of gastric cancer is low in spite of having high prevalence of *H. pylori* infection ([@B42]; [@B93]; [@B92]). Variations in bacterial and human genetic factors have been linked to explain the differences in clinical outcome, but our understanding of *H. pylori* infection and related diseases are really incomplete.

Microbiota is the ecological community of commensal, symbiotic and pathogenic microorganisms that literally share our body space. Microbiome is the combined genomes of the microbiota ([@B53]). Recent metagenomic analyses of DNA isolated from gastric tissue specimens show that human stomach is the niche of many bacterial species ([@B58]). While the exact significance of the microbes that co-exist in highly acidic gastric milieu is not understood till date, it seems apparent that *H. pylori* infection can alter the dynamics of gastric microbiota ([@B2]). However, microbiota can also be modulated by several other factors like alteration in immunity due to other infections and change in lifestyle including food and beverage consumptions ([@B23]). Interestingly, almost every geographical location has unique tradition of consuming fermented foods and beverages ([@B13]). These fermented foods are rich source of bacteria, yeasts and molds and many of these microbes provide benefits to hosts and act as probiotics ([@B95],[@B97]). More intriguingly, adding purified probiotics to therapy against *H. pylori* gives better eradication rate and reduces the side effects of antibiotics ([@B111]). Unfortunately, however, the significances of the natural probiotics in traditional fermented foods and beverages are less studied in the context of *H. pylori* associated diseases. In this mini-review, we will discuss how probiotics present in different fermented foods and beverages may have a role in preventing *H. pylori* related gastric diseases.

*H. pylori* Infection and Gastric Diseases
==========================================

Presence of spiral bacilli in stomach have been reported several times during the past century, but the culture of this slow growing species remained unsuccessful until a serendipitous prolonged incubation of human gastric specimens in microaerophillic conditions during Easter holidays by Barry James Marshall and John Robin Warren ([@B25]; [@B33]; [@B102]; [@B61]). To prove Koch's postulate Barry Marshall drank pure culture of *H. pylori*, which resulted in hypochlorhydric vomiting and gastritis before he was treated with antibiotics ([@B62]). Subsequently, a huge number of studies confirmed the role of *H. pylori* virulence factors in peptic ulcer and gastric cancer and *H. pylori* was classified as a type I carcinogen by WHO ([@B59]).

*H. pylori* expresses many virulence factors, but two multitasking proteins, the vacuolating cytotoxin (VacA) and the cytotoxin-associated gene A (CagA), seem to play the most crucial role in developing the gastro-duodenal diseases. The VacA is a secreted toxin, which forms large cytoplasmic vacuoles inside the host cells ([@B54]). The VacA is also involved in reducing mitochondrial transmembrane potential, releasing cytochrome c, inducing cell death, activating MAP-kinases and inhibiting T-cell activation ([@B34]; [@B35]; [@B103]; [@B108]; [@B98]). The *vacA* gene has mosaic structures viz. s1/s2 alleles (encoding signal peptides), m1/m2 alleles (encoding mid-regions) and i1/i2/i3 (encoding intermediate regions) ([@B17]; [@B5], [@B6]; [@B80]). The s1 and the i1 alleles of *vacA* are associated with aggressive clinical outcomes ([@B80]; [@B106]). The *H. pylori* strains carrying *vacA* s1 usually carry *cagA* gene, which is located in the *cag-*pathogenicity island ([@B12]; [@B105]; [@B106]). The *cagA^+^* strains are associated with more severe diseases in most regions ([@B12]). The *cagA* gene shows length polymorphism at the 3′ end and this variable region encodes EPIYA motifs that undergo phosphorylation once the CagA protein is translocated into the host cells ([@B107]; [@B40]). The phospho-CagA interacts and deregulates the SHP-2 protein, which leads to cancer, but the CagA can hijack cellular pathways also by phosphorylation independent manner ([@B40]; [@B38]).

Polymorphisms in host immune genes also contribute to determine the clinical status of the host ([@B21]). For example, polymorphisms in interleukin-1 (IL1) and tumour necrosis factor (TNF) genes have been shown to play important roles in progression of gastric diseases among Scottish, Japanese, American, and Indian populations ([@B28]; [@B21]). Moreover, every geographic region has unique lifestyle including food and beverage intakes, which are known to have effects on gut microbiota ([@B23]).

It is now appreciated that human stomach microbiota consists of 44 bacterial phyla, dominated by four phyla: Proteobacteria, Firmicutes, Actinobacteria, and Bacteroidetes ([@B58]). A study using Swedish patients showed that the presence of *H. pylori* in stomach may significantly alter the relative abundance of other bacteria ([@B2]). Colonization by specific groups of bacteria seems to correlate with *H. pylori* infection status. *H. pylori* colonization dramatically reduced the diversity and increased the colonization of Proteobacteria. Positive *H. pylori* status in America is also associated with increased abundance of Proteobacteria, Spirochetes and Acidobacteria, and with decreased abundance of Actinobacteria, Bacteroidetes and Firmicutes ([@B58]). Recently, in mouse, it has been shown that *H. pylori* colonization can influence both gastric and intestinal microbiota ([@B47]). While it appears that the stomach and intestinal microbiota in the presence and in the absence of *H. pylori* infection may have a role in gastric diseases the mechanism is not known.

Treatment for all *H. pylori* infections has been recommended for several geographical locations ([@B92]; [@B60]). The usual treatment regimen for *H. pylori* is a short course of two antibiotics (mostly clarithromycin and amoxicillin) along with proton pump inhibitors (e.g., omeprazole or lansoprazole). The treatment, however, is complicated by several factors like bacterial resistance to antibiotics, re-infection, side effects (bloating, diarrhea and taste disturbances) and alteration of healthy gut microbiota ([@B60]; [@B111]). The destruction of the commensal flora may lead to increased prevalence of opportunistic pathobionts, like *Clostridium difficile* ([@B60]). Hence, the treatment of *H. pylori* using antibiotics has the risk for microbiota imbalance or dysbiosis, which may lead to other diseases. Also, eradication of *H. pylori* may lead to esophageal cancer ([@B10]; [@B11]). Therefore, alternative approach that can eradicate or prevent *H. pylori* infection without affecting gut microbiota is needed.

Use of Probiotics for the Eradication of *H. pylori*
====================================================

Probiotics (means 'for life') are live microorganisms which provide beneficial effects when taken in sufficient quantity. Examples include several species of *Lactobacillus, Bifidobacterium, Enterococcus, Lactococcus, Streptococcus* as well as *Saccharomyces* ([@B79]; [@B30]). Probiotics are known to have beneficial roles in curing antibiotic associated diarrhea, constipation, traveler's diarrhea, food allergies and cancer ([@B64]; [@B15]; [@B39]; [@B44]; [@B85]).

*Lactobacillus* is normally present in human intestinal tract including stomach and it is tolerant to acid and bile ([@B84]). Therefore, *Lactobacillus* is an attractive candidate for probiotic for the treatment of *H. pylori* related gastric diseases. [@B9] showed that the culture supernatant of *Lactobacillus acidophilus* inhibits *H. pylori in vitro* due to an extracellular secretory product. Direct application of *L. acidophilus* on blood agar plate can also inhibit *H. pylori* ([@B100]). Subsequently, it was found that both *L. acidophilus* and *L. casei* subsp. *rhamnosus* can inhibit *H. pylori* due to the production of lactic acid ([@B66]; [@B29]). The lactic acid produced by *L. casei* strain Shirota inhibits 70% of urease activity *in vitro* and significantly reduces the levels of *H. pylori* colonization in mouse model ([@B91]). [@B56] studied antibacterial activity of 17 *Lactobacillus* strains on 10 *H. pylori* strains and concluded that the inhibition was due to acid production. They also found that autolysis of *L. acidophilus* after 24 h of culture releases a proteinaceous compound and this event is related to the bactericidal effect ([@B56]). Furthermore, *H. pylori* colonized mice when treated with a commercial mixture of live probiotics (*L. rhamnosus*, strain R0011, and *L. acidophilus*, strain R0052) they suppressed colonization of *H. pylori* strain SS1 ([@B45]).

The sulfatide-binding protein of the *L. reuteri* competes and binds to the gangliotetraosylceramide (asialo-GM1) and sulfatide, which are putative receptors of *H. pylori* ([@B68]). *Weissella confusa* can inhibit *H. pylori* adherence to human gastric cell line by 90%. ([@B70]).

*H. pylori* infected MKN45 cells showed increased expression of Smad7 and NFkB, and induced pro-inflammatory cytokines IL-8 and TNF-α *in vitro*. Probiotic *L. acidophilus* pre-treatment, however, inactivate the Smad7 and NFkB pathways and reduces the *H. pylori* induced inflammation ([@B109]). Using gnotobiotic murine model, it was shown that *L. salivarius* infection also inhibits the colonization of *H. pylori* and associated inflammatory responses like IL-8 release ([@B46]; [@B7]).

Since *in vitro* experiments and *in vivo* mouse studies showed promising results, a significant number of clinical trials have been performed in the recent past (**Table [1](#T1){ref-type="table"}**). Several meta-analyses published in 2013 revealed that addition of probiotics in triple therapy against *H. pylori* improves overall efficacy and reduces the side effects of therapy like nausea, diarrhea metallic taste, abdominal/epigastric pain ([@B83]). However, it needs further improvement since the benefits conferred by the probiotics are often not too remarkable. For example, a meta-analysis based on literature search strategy suggest that use of probiotics (mostly *Lactobacillus, Bifidobacterium* and *Streptococcus* and in few trials *Enterococcus, Clostridium, Saccharomyces* etc) in triple therapy improve eradication rate of *H. pylori* by ∼10% and reduce adverse effects of therapy by ∼15% ([@B111]).

###### 

Some of the anti-*Helicobacter pylori* clinical trials and meta-analyses that used probiotics.

  Study                                                                            Species                                                                                                               Results                                                                                                                    Reference
  -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- -----------
  Meta-analysis                                                                    *Lactobacillus* strains                                                                                               Improvement in eradication rates                                                                                           [@B112]
  Randomized open label clinical study                                             *Bifidus infantis*                                                                                                    Used as adjuvant improves cure rate                                                                                        [@B18]
  Meta-analysis                                                                    *Lactobacillus* and *Bifidobacterium* species                                                                         Beneficial effects on eradication rate and incidence of side effect                                                        [@B101]
  Meta-analysis                                                                    *Lactobacillus acidophilus, Lactobacillus casei* DN-114001, *Lactobacillus gasseri, Bifidobacterium infantis* 2036.   Increases eradication rates                                                                                                [@B19]
  Clinical trials                                                                  *Lactobacillus gasseri* OLL2716(LG21)                                                                                 Supression of *H. pylori*, reduction in gastric mucosal inflammation                                                       [@B90]
  Double blind randomized placebo-controlled crossover clinical study              *Lactobacillus reuteri* strain SD2112                                                                                 Suppression of urease activity and *H. pylori* density                                                                     [@B43]
  Double blind placebo-controlled study                                            *Lactobacillus reuteri* ATCC 55730                                                                                    Suppresses *H. pylori* infection, decreases the occurrence of dyspeptic symptoms                                           [@B31]
  Double blind placebo-controlled study                                            *Lactobacillus reuteri* ATCC 55730                                                                                    *H. pylori* eradicated in half of the patients by omeprazole plus *L. reuteri*                                             [@B87]
  Double blind randomized placebo-controlled study                                 *Lactobacillus reuteri* DSM 17938, *Lactobacillus reuteri* ATCC PTA 6475                                              Combination of both strains alone exert an inhibitory effect and when used with eradication therapy reduces side effects   [@B32]
  Open label single center study                                                   *Lactobacillus reuteri* DSM 17938                                                                                     Reduction of urease activity                                                                                               [@B26]
  Single center, double-blind, prospective, randomized, placebo-controlled trial   *Lactobacillus GG*                                                                                                    Reduced side effects and overall treatment tolerability                                                                    [@B4]

Role of Fermented Foods and Beverages Against *H. pylori* Associated Diseases
=============================================================================

Fermentation of food dates back to the early ages of human evolution and provides an effective way of preserving food for longer durations ([@B65]). Many of the bacteria, yeasts and molds that are present in fermented foods and beverages are known probiotics and probably provide health benefits when consumed raw ([@B94]). The significance of the microbes present in fermented food in maintaining human health was first noticed by Elie Metchnikoff ([@B57]). He hypothesized that the long and healthy lives of Bulgarian peasants were due to the regular consumption of sour milk and yogurt containing the necessary beneficial microbes ([@B57]).

Many of the probiotic that are isolated directly from the fermented foods, particularly fermented dairy products, have anti *H. pylori* effects. Based on dietary interviews it was found that yogurt, but not unfermented dairy products, when consumed one serving per week or more has protective effect against *H. pylori* infection in Mexican population ([@B74]). Several strains of *Lactobacilli* and two strains of yeast directly isolated from yogurt were found to have inhibitory effect on *H. pylori* ([@B72]). A meta-analysis of randomized controlled trials shows that there is ∼10% improvement in eradication rates when using fermented milk based probiotics, which seems to be better than capsule/sachet-based bacteria-only preparations ([@B86]). Similarly, 4-week treatment with *L. gasseri*-containing yogurt improved the efficacy of triple therapy in patients with *H. pylori* infection ([@B24]). Another study showed that *H. pylori* infected children have a lower number of *Bifidobacterium* in their gut, but intake of probiotics-containing yogurt had multiple effects like, restoration of *Bifidobacterium*, reduction of *H. pylori* load, increase in IgA and decrease in IL-6 ([@B110]). Three strains of lactic acid bacteria, LY1, LY5 AND IF22, which are from the spent culture supernatant of fermented milk, showed anti-*H. pylori* effect ([@B55]). In china, several probiotics from traditional fermented foods were isolated and two strains of *Lactobacillus- L. plantarum 18* and *L. gasseri* showed potential anti-*H. pylori* activity ([@B14]). Kefir, a fermented milk product was found to be effective in eradication and reducing side effects when used along with triple therapy ([@B8]). An *in vitro* study proved that *L. plantarum* (MLBPL1) isolated from sauerkraut (fermented cabbage) had an anti-*Helicobacter* activity ([@B82]). Interestingly, the main inhibitory activity is mostly associated with cell wall.

Unfortunately, however, anti-*H. pylori* activity alone does not ensure protection from gastric diseases and gastric cancer may sometimes develop even after eradication of *H. pylori* since some of the *H. pylori* proteins like CagA may act by 'hit and run' mechanism ([@B92]; [@B38]). More interestingly, prevalence of *H. pylori* and incidence of gastric diseases does not match in some countries. In Africa and India, the prevalence of *H. pylori* infection and associated gastritis is high, but the incidence of gastric cancer is very low ([@B42]; [@B93]). On the other hand, East-Asian countries like Japan and Korea have high rates of gastric cancer ([@B93]). Genotype alone cannot be responsible to explain the clinical outcome since nearly all *H. pylori* strains isolated from East-Asia are virulent ([@B92]). Therefore, it is intriguing to compare the microbes that are present in traditional fermented foods and beverages of Japan or Korea and African countries (**Table [2](#T2){ref-type="table"}**). Apparently, fermented foods in African countries are based on milk, beans, grains and roots. They are dominated by *Lactobacillus* and other lactic acid bacteria. Conversely, Japanese fermented foods are primarily based on rice, soy and fish and these foods have varieties of bacteria and fungi. Interestingly, the soy foods may reduce the risk for gastric cancer, while high salt containing foods might be a risk factor in Japan and Korea ([@B41]; [@B104]).

###### 

Microbes present in traditional fermented foods and beverages in Japan and Africa.

  Fermented food                          Ingredients                                        Microorganism                                                                                                                           Known probiotics or anti-*H. pylori* activity                           Country                            Reference
  --------------------------------------- -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------- ---------------
  **Fermented food of Japan and Korea**                                                                                                                                                                                                                                                                                                         
  Sake                                    Rice                                               *Aspergillus sojae, Bacillus subtilis* and lactic acid bacteria                                                                         Lactic acid bacteria and *Bacillus subtilis*                            Japan                              [@B88],[@B89]
  Narezushi                               Fish, salt and cooked rice                         *L. plantarum* and *L. brevis*                                                                                                          *L. plantarum*                                                          Japan                              [@B49]
  Takju                                   Rice                                               *Lb. harbinensis, Lb. parabuchneri Lactobacillus (Lb.) paracasei, Lb. plantarum*, and *Leuconostoc pseudomesenteroides*                 *L. plantarum*                                                          Korea                              [@B48]
  Vinegar                                 Rice                                               *Aspergillus oryzae, Lactobacillus acetotolerance, Acetobacter pasteurianus, Saccharomyces* sp. and lactic acid bacteria                Lactic acid bacteria and *Saccharomyces* sp.                            Japan                              [@B37]
  Natto                                   Soybean                                            *Bacillus subtilis*                                                                                                                     *Bacillus subtilis*                                                     Japan                              [@B51]
  Starch Noodle                           Starch from sweet potato, mung bean etc            *L. casei, L. cellobiosus, L. fermenti*                                                                                                 *L. casei*                                                              Korea, Japan                       [@B81]
  Kimchi                                  Korean cabbage, radish, various vegetables, salt   *L. mesenteroides, L. brevis, L. plantarum*                                                                                             *L. plantarum*                                                          Korea                              [@B81]
  Miso                                    Soybean and sometime rice or barley                *Aspergillus oryzae Saccharomyces cerevisiae and lactic acid bacteria*                                                                  Lactic acid bacteria and *Saccharomyces* sp.                            Japan                              [@B41]
  Komesu and kurosu                       Rice                                               *Aspergillus oryzae, Saccharomyces cerevisiae* and acetic acid bacteria                                                                 *Saccharomyces* sp.                                                     Japan                              [@B71]
  Tempeh                                  Soybean                                            *Rhizopus* sp.                                                                                                                          ?                                                                       Japan                              [@B3]
  **Fermented food of Africa**                                                                                                                                                                                                                                                                                                                  
  Rigouta                                 Milk                                               *Lactococcus lactis and Enterococcus faecalis*                                                                                          *Enterococcus faecalis*                                                 Tunisia                            [@B36]
  Wara                                    Cow milk                                           *Lactobacillus plantarum* and other lactic acid bacteria                                                                                *Lactobacillus plantarum* and other lactic acid bacteria                Nigeria                            [@B73]
  Ugba                                    Oil bean seed                                      *Bacillus subtilis*                                                                                                                     *Bacillus subtilis*                                                     Nigeria                            [@B73]
  Fufu                                    Cassava                                            *Lactobacillus plantarum* and other lactic acid bacteria                                                                                *Lactobacillus plantarum* and other lactic acid bacteria                Nigeria                            [@B73]
  Ogi                                     Maize                                              *Lactobacillus plantarum* and other lactic acid bacteria                                                                                *Lactobacillus plantarum* and other lactic acid bacteria                Nigeria                            [@B73]
  Kunu-zarki                              Millet                                             *Lactobacillus plantarum* and other lactic acid bacteria                                                                                *Lactobacillus plantarum* and other lactic acid bacteria                Nigeria                            [@B73]
  Kenkey                                  Maize                                              *Lactobacillus plantarum* and other lactic acid bacteria                                                                                *Lactobacillus plantarum* and other lactic acid bacteria                Nigeria                            [@B73]
  Iru                                     African locust bean                                *Lactobacillus plantarum* and other lactic acid bacteria                                                                                *Lactobacillus plantarum* and other lactic acid bacteria                Nigeria                            [@B73]
  Garri                                   Cassava                                            Yeast, *Lactobacillus plantarum, Leuconostoc fallax, Lactobacillus fermentum* and other lactic acid bacteria                            *Lactobacillus plantarum* and other lactic acid bacteria                Nigeria and other part of Africa   [@B50]
  Kule naoto                              Milk                                               *Lactobacillus plantarum* and other lactic acid bacteria                                                                                *Lactobacillus plantarum* and other lactic acid bacteria                Maasai in Kenya                    [@B63]
  Poto Poto                               Maize dough                                        *Lactobacillus plantarum, Bacillus* sp., *Lactobacillus reuteri, Lactobacillus casei* and other lactic acid bacteria                    *Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus casei*   Congo                              [@B1]
  Degue                                   Pearl millet dough                                 *Lactobacillus plantarum, Bacillus* sp., *Lactobacillus reuteri, Lactobacillus casei*, other lactic acid bacteria and yeast and molds   *Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus casei*   Burkina Faso                       [@B1]

A similar comparison would be exiting between the fermented foods of ethnic populations in North-Eastern India (e.g., ethnic populations in Sikkim state like Bhutias) and Mid-Eastern India (e.g., ethnic population of Jharkhand and West Bengal states like Santhals). North-Eastern states have highest incidence of gastric cancer in India ([@B78]). This high prevalence has been thought to be due to smoking and high salt consumption that possibly come from fermented and pickled foods including fish and meat ([@B76]; [@B99]). Recent analyses of some of the fermented foods showed presence of huge microbial variety but their significances in gastric diseases have not been studied ([@B96]; [@B95],[@B97]). Unfortunately, not much is known about the microbes that are present in fermented foods consumed by the Santhals. But interestingly, they regularly consume intoxicating alcoholic beverages like Handia and Mahua fermented in traditional way and these beverages are not common elsewhere ([@B52]). Among Santhals, infections with virulent *H. pylori* strains are extremely common without any manifestation of gastric diseases ([@B20]).

Our current understandings of microbes present in the ethnic fermented foods are incomplete at present, but with modern methodologies like metagenomic analysis using Next-generation sequencing the microbial species are now easy to identify ([@B67]). However, to prove or disprove the hypothesis---whether or not microbes present in the ethnic fermented food can protect certain population from peptic ulcer or gastric cancer is very tricky, particularly when *H. pylori* infection is not the only determinant in precipitating the gastric diseases ([@B75]; [@B22]). How the microbes present in the ethnic fermented food can alter the pathogenicity of *H. pylori* in combination with gastric and duodenal microbiome as well as host immunity for different population is perhaps the key question at present.

Conclusion
==========

*H. pylori* infection is the major risk factor for peptic ulcer and gastric cancer and the eradication of this bacterium using antibiotics is often unsuccessful. Several microbes with known probiotic activities are shown to have inhibitory effects against *H. pylori in vitro* and *in vivo*. Inclusion of probiotics in triple therapy leads to improved efficacy and reduced side effects. Most traditional fermented foods and beverages are natural sources of probiotic microbes. Microbes directly isolated from the fermented products are shown to have anti-*H. pylori* activity. Few studies showed that consumption of probiotics containing yogurt and kefir are somewhat beneficial in the context of *H. pylori* infection. Many ethnic populations have significantly low incidences of peptic ulcer and gastric cancer in spite of having very high prevalence of *H. pylori* infection. Incidentally, each ethnic population also has unique tradition of consuming fermented food and beverages that contain probiotics. It is intriguing to hypothesize that regular consumptions of these probiotics may have protective effect against peptic ulcer and gastric cancer for some populations. Analyzing these traditional fermented foods and beverages using modern techniques is needed to understand these microbes and their significances.
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